Publications

Recent Publications (2021 - July 2025)

1. Mercier A, De Leiris N, Calais J, Ludwig VB, Farolfi A, Gafita A, Djaileb L. PSMA/FDG discordance: 24-hour [177Lu]-PSMA-617 SPECT versus 60-minute [68Ga]-PSMA-11 PET. Eur J Nucl Med Mol Imaging. Published online July 24, 2025. doi:10.1007/s00259-025-07482-x
2. Juarez Casillas JE, Nikitas J, Rettig MB, Reiter RE, Lee A, Steinberg ML, Valle L, Kalbasi TR, Calais J, Czernin J, Eala MA, Tsai S, Kane N, Solanki AA, Sexton R, Duriset S, Berenji GR, Aronson WJ, Garraway IP, Chang MG, Kwon R, Lee SP, Nickols NG, Kishan AU. Pooled Analysis of the SOLAR and SATURN Clinical Trials Comparing Progression of Synchronous Versus Metachronous Prostate-specific Membrane Antigen-defined Oligometastatic Prostate Cancer Following Systemic and Tumor-directed Therapy. Eur Urol Oncol. Published online June 19, 2025. doi:10.1016/j.euo.2025.05.027
3. Kuo PH, Calais J, Crosby M. PSMA PET Imaging in the Management of Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Radioligand Therapy. Target Oncol. Published online May 26, 2025. doi:10.1007/s11523-025-01151-7
4. Czernin J, Anderson CJ, Badawi RD, Barthel H, Bengel FM, Beyer T, Buvat I, Calais J, Dorbala S, Drzezga AE, Herrmann K, Hope TA, Jadvar H, Mankoff DA, Schelbert HR, Weber WA. Funding Reductions Threaten the Future of Medical Innovation. J Nucl Med. 2025;66(6):829. Published 2025 Jun 2. doi:10.2967/jnumed.125.270157
5. Gafita A, Djaileb L, Calais J, Eiber M, Fendler WP. RECIP 1.0: A Roadmap for Clinical Implementation. J Nucl Med. 2025;66(5):673-675. Published 2025 May 1. doi:10.2967/jnumed.124.268730
6. Karpinski MJ, Rahbar K, Bagemann M, Nikoukar LR, Schafers M, Hoberück S, Miederer M, Holscher T, Rasul S, Miszczyk M, Lanfranchi F, Bauckneht M, Pfob CH, Kind F, Goffin K, Husing A, Kesch C, Herrmann K, Stuschke M, Gafita A, Husing J, Calais J, Hofman MS, Hope TA, Miksch J, Soeterik TFW, Di Giorgio A, Farolfi A, Bjartell A, Tragardh E, Unterrainer LM, Holzgreve A, Sheikh GT, Rauscher I, Eiber M, Hadaschik BA, Fendler WP. Updated Prostate Cancer Risk Groups by Prostate-specific Membrane Antigen Positron Emission Tomography Prostate Cancer Molecular Imaging Standardized Evaluation (PPP2): Results from an International Multicentre Registry Study. Eur Urol. Published online May 2, 2025. doi:10.1016/j.eururo.2025.04.017
7. Unterrainer LM, Farolfi A, Grogan T, Hotta M, Djaileb L, Gafita A, Sonni I, Rettig MB, Rosar F, Ezziddin S, Denis CS, de Kouchkovsky I, Aggarwal R, Emmett L, Hope TA, Czernin J, Calais J. Early changes of PSMA PET expression after initiation of androgen receptor signaling inhibitors in CRPC: an international multicenter retrospective study. Eur J Nucl Med Mol Imaging. Published online March 26, 2025. doi:10.1007/s00259-025-07178-2
8. Hotta M, Nguyen K, Thin P, Armstron WR, Sonni I, Farolfi A, Steinberg M, Czernin J, Nickols NG, Kishan AU, Calais J. Kinetics of PSMA PET signal after radiotherapy in prostate cancer lesions: A single-center retrospective study. Radiother Oncol. 2025;207:110869. doi:10.1016/j.radonc.2025.110869
9. Murthy V, Ludwig V, Gafita A, Hope TA, Calais J. The Role of PSMA PET Parameters as Biomarkers for Response to PSMA-Targeted Radiopharmaceutical Therapy. J Nucl Med. 2025;66(6):833-838. Published 2025 Jun 2. doi:10.2967/jnumed.124.268818
10. Ells Z, Ludwig V, Weiner AB, Kimura K, Farolfi A, Chamie K, Shirk J, Donin NM, Reiter R, Czernin J, Calais J (co-last author), Dahlbom M. A free method for patient-specific 3D-VR anatomical modeling for presurgical planning using DICOM images and open-source software. Methods. 2025;236:10-16. doi:10.1016/j.ymeth.2025.02.006
11. Unterrainer LM, Hope TA, Fendler WP, Grogan T, Ndlovu H, Armstrong W, Barbato F, Benz MR, Rettig MB, Kishan AU, Sathekge M, Herrmann K, Czernin J, Calais J. Low- and High-Volume Disease in Metastatic Hormone-Sensitive Prostate Cancer: From CHAARTED to PSMA PET-An International Multicenter Retrospective Study. J Nucl Med. 2025 Jan 3;66(1):54-60. doi: 10.2967/jnumed.124.268441. PMID: 39753363
12. Holzgreve A, Armstrong WR, Clark KJ, Benz MR, Smith CP, Djaileb L, Gafita A, Thin P, Nickols NG, Kishan AU, Rettig MB, Reiter RE, Czernin J, Calais J. PSMA-PET/CT Findings in Patients With High-Risk Biochemically Recurrent Prostate Cancer With No Metastatic Disease by Conventional Imaging. JAMA Netw Open. 2025 Jan 2;8(1):e2452971. doi: 10.1001/jamanetworkopen.2024.52971. PMID: 39752157
    MedPageToday: PSMA-PET/CT Detects Metastatic Prostate Cancer Missed by Other Imaging
    AZO Optics: PSMA-PET Challenges Traditional Staging of High-Risk Prostate Cancer
    Renal + Neurology News: PSMA-PET Detects Hidden Metastasis in Recurrent Prostate Cancer
    Inside Precision Medicine: Prostate Cancer Spread Missed By Conventional Imaging
    Urology Times: Conventional imaging may understage prostate cancer, new data suggest
    AuntMinnie: PSMA-PET/CT bests conventional imaging for prostate cancer diagnosis
    The University Network (TUN): Breakthrough PSMA-PET Imaging Reveals Hidden Metastases in Prostate Cancer
    The ASCO Post: Advanced Imaging May Uncover Hidden Metastases in High-Risk Prostate Cancer Cases
    Diagnostic Imaging: Study Emphasizes PSMA PET Staging of High-Risk, Hormone Sensitive Prostate Cancer
    OncoDaily: UCLA: Advanced imaging uncovered hidden metastases in high-risk prostate cancer cases
    UCLA Newsroom: Advanced imaging uncovers hidden metastases in high-risk prostate cancer cases
    Science Daily: Advanced imaging uncovers hidden metastases in high-risk prostate cancer cases
13. Unterrainer LM, Hope TA, Fendler WP, Grogan T, Ndlovu H, Armstrong W, Barbato F, Benz MR, Rettig MB, Kishan AU, Sathekge M, Herrmann K, Czernin J, Calais J.Low- and High-Volume Disease in Metastatic Hormone-Sensitive Prostate Cancer: From CHAARTED to PSMA PET-An International Multicenter Retrospective Study. J Nucl Med. 2025 Jan 3;66(1):54-60. doi: 10.2967/jnumed.124.268441. PMID: 39753363
    Urology Times: Addition of PSMA PET led to notable stage migration in mHSPC, study shows
14. Weiner AB, Ells Z, Meyer C, Dahlbom M, Sennung D, Varughese D, Ludwig VB, Carlucci G, Grant R, Czernin J, Calais J(co-last author), Reiter RE. Clinical Responses to Prostate-specific Membrane Antigen Radioguided Salvage Lymphadenectomy for Prostate Cancer Recurrence: Results from a Prospective Exploratory Trial. Eur Urol Open Sci. 2024 Oct 15;70:36-42. doi: 10.1016/j.euros.2024.09.004. eCollection 2024 Dec. PMID: 39483519
15. Sonni I, Weiner AB, Doddipalli S, Deol M, Ban D, Kim HO, Grogan T, Ahuja P, Barroso N, Zong Y, Soin P, Sisk A, Czernin J, Hsu W, Calais J, Reiter RE, Raman SS. Clinical, Pathologic, and Imaging Variables Associated with Prostate Cancer Detection by PSMA PET/CT and Multiparametric MRI. J Nucl Med. 2024;65(12):1923-1931. Published 2024 Dec 3. doi:10.2967/jnumed.124.268443
    UroToday: Clinical, Pathologic, and Imaging Variables Associated with Prostate Cancer Detection by PSMA PET/CT and Multiparametric MRI
16. Huang RR, Zuo C, Mona CE, Holzgreve A, Morrissey C, Nelson PS, Brady L, True L, Sisk A, Czernin J, Calais J, Ye H. FAP and PSMA Expression by Immunohistochemistry and PET Imaging in Castration-Resistant Prostate Cancer: A Translational Pilot Study. J Nucl Med. 2024 Oct 30:jnumed.124.268037. doi: 10.2967/jnumed.124.268037. PMID: 39477498
    UroToday: FAP and PSMA Expression by Immunohistochemistry and PET Imaging in Castration-Resistant Prostate Cancer: A Translational Pilot Study
17. Nikitas J, Gafita A, Benz MR, Djaïleb L, Farolfi A, Hotta M, Sonni I, Alano R, Rettig M, Shen J, Armstrong W, Grogan T, Liu S, Czernin J, Calais J. Phase 2 trial of PSMA PET CT versus planar bone scan and CT in prostate cancer patients progressing while on androgen deprivation therapy.
    Sci Rep. 2024 Oct 18;14(1):24411. doi: 10.1038/s41598-024-75589-6. PMID: 39420060
    Urology Times: Jeremie Calais, MD, highlights study of PSMA-PET vs bone scan in metastatic prostate cancer
18. Hotta M, Kim GHJ, Rerkpichaisuth V, Teng PY, Armstrong WR, Carlucci G, Dahlbom M, Abtin F, Lari SM, Fishbein GA, Czernin J, Volkmann ER, Weigt SS, Calais J. Correlation of FAPI PET Uptake with Immunohistochemistry in Explanted Lungs from Patients with Advanced Interstitial Lung Disease. J Nucl Med. 2024 Nov 1;65(11):1789-1794. doi: 10.2967/jnumed.124.268351. PMID: 39362770
19. Murthy V, Voter AF, Nguyen K, Allen-Auerbach M, Chen L, Caputo S, Ledet E, Akerele A, Moradi Tuchayi A, Lawhn-Heath C, Wang T, Carducci MA, Pomper MG, Paller CJ, Czernin J, Solnes LB, Hope TA, Sartor O, Calais J (co-last author), Gafita A. Efficacy and Toxicity of [177Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: Results from the U.S. Expanded-Access Program and Comparisons with Phase 3 VISION Data. J Nucl Med. 2024 Nov 1;65(11):1740-1744. doi: 10.2967/jnumed.124.267816. PMID: 39327018
    UroToday: Efficacy and Toxicity of [177Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: Results from the U.S. Expanded-Access Program and Comparisons with Phase 3 VISION Data
20. Weiner AB, Agrawal R, Wang NK, Sonni I, Li EV, Arbet J, Zhang JJH, Proudfoot JA, Hong BH, Davicioni E, Kane N, Valle LF, Kishan AU, Pra AD, Ghadjar P, Sweeney CJ, Nickols NG, Karnes RJ, Shen J, Rettig MB, Czernin J, Ross AE, Lee Kiang Chua M, Schaeffer EM, Calais J, Boutros PC, Reiter RE. Molecular Hallmarks of Prostate-specific Membrane Antigen in Treatment-naïve Prostate Cancer. Eur Urol. 2024 Sep 17:S0302-2838(24)02597-1. doi: 10.1016/j.eururo.2024.09.005. PMID: 39294048
    Urology Times: PSMA levels linked to tumor biology, treatment sensitivity in treatment-naïve prostate cancer
21. Thin P, Hotta M, Gafita A, Grogan T, Czernin J, Calais J (co-last author), Sonni I. Clinical Factors That Influence Repeat 68Ga-PSMA-11 PET/CT Scan Positivity in Patients with Recurrent Prostate Cancer Under Observation After a Negative 68Ga-PSMA-11 PET/CT Scan: A Single-Center Retrospective Study. J Nucl Med. 2024 Aug 21:jnumed.124.267591. doi: 10.2967/jnumed.124.267591 PMID: 39168522
    UroToday: Clinical Factors That Influence Repeat 68Ga-PSMA-11 PET/CT Scan Positivity in Patients with Recurrent Prostate Cancer Under Observation After a Negative 68Ga-PSMA-11 PET/CT Scan: A Single-Center Retrospective Study
22. Nikitas J, Castellanos Rieger A, Farolfi A, Seyedroudbari A, Kishan AU, Nickols NG, Steinberg ML, Valle LF, Rettig M, Czernin J, Calais J. Prostate-Specific Membrane Antigen PET/CT-Guided, Metastasis-Directed Radiotherapy for Oligometastatic Castration-Resistant Prostate Cancer. J Nucl Med. 2024 Aug 1:jnumed.124.267922. doi: 10.2967/jnumed.124.267922. PMID: 39089811
    UroToday: Prostate-Specific Membrane Antigen PET/CT-Guided, Metastasis-Directed Radiotherapy for Oligometastatic Castration-Resistant Prostate Cancer
    Diagnostic Imaging: Can Targeted PSMA PET/CT-Guided Radiotherapy Have an Impact for Oligometastatic Prostate Cancer?
23. Emmett L, Papa N, Hope TA, Fendler W, Calais J, Burger I, Eiber M, Barbato F, Moon D, Counter W, John N, Xue A, Franklin A, Thompson J, Rasiah K, Frydenberg M, Yaxley J, Buteau J, Agrawal S, Ho B, Nguyen A, Liu V, Lee J, Woo H, Hsiao E, Sutherland T, Perry E, Stricker P, Hofman MS, Kasivisvanathan V, Roberts M, Murphy D. Beyond Prostate Imaging Reporting and Data System: Combining Magnetic Resonance Imaging Prostate Imaging Reporting and Data System and Prostate-Specific Membrane Antigen-Positron Emission Tomography/Computed Tomography PRIMARY Score in a Composite (P) Score for More Accurate Diagnosis of Clinically Significant Prostate Cancer. J Urol. 2024 Aug;212(2):299-309. doi: 10.1097/JU.0000000000004010. Epub 2024 May 17. PMID: 38758680
24. Nikitas J, Subramanian K, Gozal NB, Ricaurte-Fajardo A, Li E, Proudfoot JA, Davicioni E, Marciscano AE, Osborne JR, Barbieri CE, Armstrong WR, Smith CP, Valle LF, Steinberg ML, Boutros PC, Nickols NG, Rettig MB, Reiter R, Weiner AB, Calais J, Czernin J, Ross AE, Kim EH, Nagar H, Kishan AU.Transcriptomic Profiling of Primary Prostate Cancers and Nonlocalized Disease on Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography: A Multicenter Retrospective Study. JCO Precis Oncol. 2024 Jul;8:e2400161. doi: 10.1200/PO.24.00161. PMID: 39013135
25. Gafita A, Djaileb L, Rauscher I, Fendler WP, Hadaschik B, Rowe SP, Herrmann K, Solnes LB, Calais J, Rettig MB, Weber M, Farolfi A, Benz MR, Eiber M. RECIP 1.0 Predicts Progression-Free Survival After [177Lu]Lu-PSMA Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer. J Nucl Med. 2024 Apr 18:jnumed.123.267234. doi: 10.2967/jnumed.123.267234. PMID: 38637143 J Nucl Med. 2024 Apr 25:jnumed.123.267004. doi: 10.2967/jnumed.123.267004. PMID: 38664019
26. Nikitas J, Lam E, Booker KA, Fendler WP, Eiber M, Hadaschik B, Herrmann K, Hirmas N, Lanzafame H, Stuschke M, Czernin J, Steinberg ML, Nickols NG, Kishan AU, Calais J. Randomized Trial of Prostate-Specific Membrane Antigen PET/CT Before Definitive Radiotherapy for Unfavorable Intermediate- and High-Risk Prostate Cancer (PSMA-dRT Trial).
27. Nikitas J, Rettig M, Shen J, Reiter R, Lee A, Steinberg ML, Valle LF, Sachdeva A, Romero T, Calais J, Czernin J, Nickols NG, Kishan AU. Systemic and Tumor-directed Therapy for Oligorecurrent Metastatic Prostate Cancer (SATURN): Primary Endpoint Results from a Phase 2 Clinical Trial. Eur Urol. 2024;85(6):517-520. doi:10.1016/j.eururo.2024.01.021
28. Maliha PG, Hotta M, Farolfi A, Grogan T, Alano R, Limon A, Lam E, Carlucci G, Bahri S, Salavati A, Benz M, Silverman D, Gupta P, Quon A, Allen-Auerbach M, Czernin J, Calais J. FAPI PET uptake patterns after invasive medical interventions: a single center retrospective analysis. Eur J Nucl Med Mol Imaging. 2024;51(11):3373-3385. doi:10.1007/s00259-024-06733-7
29. Weber M, Fendler WP, Ravi Kumar AS, Calais J, Czernin J, Ilhan H, Saad F, Kretschmer A, Hekimsoy T, Brookman-May SD, Mundle SD, Small EJ, Smith MR, Perez PM, Hope TA, Herrmann K, Hofman MS, Eiber M, Hadaschik BA. Prostate-specific Membrane Antigen Positron Emission Tomography-detected Disease Extent and Overall Survival of Patients with High-risk Nonmetastatic Castration-resistant Prostate Cancer: An International Multicenter Retrospective Study. Eur Urol. 2024 Mar 14:S0302-2838(24)00054-X. doi: 10.1016/j.eururo.2024.01.019. PMID: 38490855
30. Armstrong WR, Kishan AU, Booker KM, Grogan TR, Elashoff D, Lam EC, Clark KJ, Steinberg ML, Fendler WP, Hope TA, Nickols NG, Czernin J, Calais J. Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography on Prostate Cancer Salvage Radiotherapy Management: Results from a Prospective Multicenter Randomized Phase 3 Trial (PSMA-SRT NCT03582774). Eur Urol. 2024;86(1):52-60. doi:10.1016/j.eururo.2024.01.012
    AuntMinnie:PSMA-PET helps plan treatment in men with relapsed prostate cancer
31. Farolfi A, Armstrong WR, Djaileb L, Gafita A, Hotta M, Allen-Auerbach M, Unterrainer LM, Fendler WP, Rettig M, Eiber M, Hofman MS, Hadaschik B, Herrmann K, Czernin J, Calais J, Benz MR. Differences and Common Ground in 177Lu-PSMA Radioligand Therapy Practice Patterns: International Survey of 95 Theranostic Centers. J Nucl Med. 2024;65(3):438-445. Published 2024 Mar 1. doi:10.2967/jnumed.123.266391
32. L Emmett, N Papa, W Counter, J Calais, F Barbato, I Burger, M Eiber, MJ. Roberts, S Agrawal, A Franklin, A Xue, K Rasiah, N John, D Moon, M Frydenberg, J Yaxley, P Stricker, K W, G Coughlin, T Gianduzzo, B Kua, B Ho, A Nguyen, V Liu, J Lee, E Hsiao, T Sutherland, E Perry, WP Fendler, TA. Hope.Reproducibility and Accuracy of the PRIMARY Score on PSMA PET and of PI-RADS on Multiparametric MRI for Prostate Cancer Diagnosis Within a Real-World Database. J Nucl Med 2023 Nov 30: jnumed.123.266164. doi: 10.2967/jnumed.123.266164. PMID: 38050155
33. Maliha PG, Hotta M, Czernin J, Calais J. Characterizing Normal Variant [68Ga]Ga-FAPI-46 Uptake in the Epididymis. J Nucl Med. 2023 Nov 9:jnumed.123.266013. doi: 10.2967/jnumed.123.266013. PMID: 37945382
34. Sonni I, Gafita A, Unterrainer LM, Alano RM, Lira S, Shen J, Drakaki A, Grogan T, Rettig MB, Czernin J, Calais J. Effects of novel androgen receptor signaling inhibitors on PSMA PET signal intensity in patients with castrate-resistant prostate cancer: a prospective exploratory serial imaging study. EJNMMI Res. 2023 Oct 30;13(1):95. doi: 10.1186/s13550-023-01048-4. PMID: 37902861
35. Meyer C, Stuparu A, Lueckerath K, Calais J, Czernin J, Slavik R, Dahlbom M. Tandem Isotope Therapy with 225Ac- and 177Lu-PSMA-617 in a Murine Model of Prostate Cancer. J Nucl Med. 2023 Nov;64(11):1772-1778. doi: 10.2967/jnumed.123.265433. PMID: 37797974
36. Murthy V, Appiah-Kubi E, Nguyen K, Thin P, Hotta M, Shen J, Drakaki A, Rettig M, Gafita A, Calais J (Co-last author), Sonni I,. Associations of quantitative whole-body PSMA-PET metrics with PSA progression status under long-term androgen deprivation therapy in prostate cancer patients: a retrospective single-center study. Eur J Hybrid Imaging. 2023 Oct 2;7(1):18. doi: 10.1186/s41824-023-00178-1. PMID: 37779132.
37. Koerber SA, Röhrich M, Walkenbach L, Liermann J, Choyke PL, Fink C, Schroeter C, Spektor AM, Herfarth K, Walle T, Calais J, Kauczor HU, Jaeger D, Debus J, Haberkorn U, Giesel FL 
    Impact of 68Ga-FAPI PET/CT on Staging and Oncologic Management in a Cohort of 226 Patients with Various Cancers. J Nucl Med. 2023 Sep 7:jnumed.123.266046. PMID: 37678928
    AuntMinnie: FAPI-PET/CT may improve treatment of cancer patients
38. Murthy V, Gafita A, Thin P, Nguyen K, Grogan T, Shen J, Drakaki A, Rettig M, Czernin J, Calais J. Prognostic Value of End-of-Treatment PSMA PET/CT in Patients Treated with 177Lu-PSMA Radioligand Therapy: A Retrospective, Single-Center Analysis. J Nucl Med. 2023 Sep 7:jnumed.122.265155. PMID: 37678927
39. Hope TA, Benz M, Jiang F, Thompson D, Barbato F, Juarez R, Hernandez Pampaloni M, Allen-Auerbach M, Gupta P, Fendler WP, Calais J. Do Bone Scans Overstage Disease Compared with PSMA PET at Initial Staging? An International Multicenter Retrospective Study with Masked Independent Readers. J Nucl Med. 2023 Aug 17:jnumed.123.265916. PMID: 37591547 
    UCSF: For Some Prostate Cancer Patients, PSMA PET May Be Better for Initial Staging of Disease
40. Gafita A, Djaileb L, Rauscher I, Fendler WP, Hadaschik B, Rowe SP, Herrmann K, Calais J, Rettig M, Eiber M, Weber M, Benz MR, Farolfi A. Response Evaluation Criteria in PSMA PET/CT (RECIP 1.0) in Metastatic Castration-resistant Prostate Cancer. Radiology. 2023 Jul;308(1):e222148. doi: 10.1148/radiol.222148. PMID: 37432081
    Pluvicto patient response criteria validated
41. Crane JN, Graham DS, Mona CE, Nelson SD, Samiei A, Dawson DW, Dry SM, Masri MG, Crompton JG, Benz MR, Czernin J, Eilber FC, Graeber TG, Calais J, Federman NC. Fibroblast Activation Protein Expression in Sarcomas. Sarcoma. 2023 Jun 9;2023:2480493. PMID: 37333052.
42. Holzgreve A, Unterrainer M, Calais J, Adams T, Oprea-Lager DE, Goffin K, Lopci E, Unterrainer LM, Kramer KKM, Schmidt-Hegemann NS, Casuscelli J, Stief CG, Ricke J, Bartenstein P, Kunz WG, Mehrens D. Is PSMA PET/CT cost-effective for the primary staging in prostate cancer? First results for European countries and the USA based on the proPSMA trial. Eur J Nucl Med Mol Imaging. 2023 Jul 10. doi: 10.1007/s00259-023-06332-y. PMID: 37428216
43. Djaïleb L, Armstrong WR, Thompson D, Gafita A, Farolfi A, Rajagopal A, Grogan TR, Nguyen K, Benz MR, Hotta M, Barbato F, Ceci F, Schwarzenböck SM, Unterrainer M, Zacho HD, Juarez R, Cooperberg M, Carroll P, Washington S, Reiter RE, Eiber M, Herrmann K, Fendler WP, Czernin J, Hope TA, Calais J. Presurgical 68Ga-PSMA-11 Positron Emission Tomography for Biochemical Recurrence Risk Assessment: A Follow-up Analysis of a Multicenter Prospective Phase 3 Imaging Trial. Eur Urol. 2023 Jul 21:S0302-2838(23)02955-X. PMID: 37482512
    Health Day: PSMA-PET Improves Prediction of Biochemical Recurrence in Prostate Cancer
    UCLA Health Newsroom: PSMA PET imaging improves accuracy of predicting prostate cancer recurrence
    Ecancer: PSMA PET imaging improves accuracy of predicting prostate cancer recurrence
    Urology Times: PSMA-PET shows value as a prognostic biomarker for recurrence in prostate cancer
44. Fizazi K, Herrmann K, Krause BJ, Rahbar K, Chi KN, Morris MJ, Sartor O, Tagawa ST, Kendi AT, Vogelzang N, Calais J, Nagarajah J, Wei XX, Koshkin VS, Beauregard JM, Chang B, Ghouse R, DeSilvio M, Messmann RA, de Bono J. Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2023 Jun;24(6):597-610. doi: 10.1016/S1470-2045(23)00158-4. PMID: 37269841
45. Kuo PH, Yoo DC, Avery R, Seltzer M, Calais J, Nagarajah J, Weber WA, Fendler WP, Hofman MS, Krause BJ, Brackman M, Kpamegan E, Ghebremariam S, Benson T, Catafau AM, Kendi AT. A VISION Substudy of Reader Agreement on 68Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for 177Lu-PSMA-617 Radioligand Therapy. J Nucl Med. 2023 Aug;64(8):1259-1265. PMID: 37230533
46. Hotta M, Gafita A, Murthy V, Benz MR, Sonni I, Burger IA, Eiber M, Emmett L, Farolfi A, Fendler WP, Weber MM, Hofman MS, Hope TA, Kratochwil C, Czernin J, Calais J. PSMA PET Tumor-to-Salivary Gland Ratio to Predict Response to [177Lu]PSMA Radioligand Therapy: An International Multicenter Retrospective Study. J Nucl Med. 2023 Mar 30:jnumed.122.265242. doi: 10.2967/jnumed.122.265242. PMID: 36997329 + Featured article of the month + 
    Mirage News: New PSG Score Improves Patient Selection for PSMA Radiopharmaceutical Therapy
    Newly Developed PSG Score Improves Patient Selection for PSMA Radiopharmaceutical Therapy
    VJOncology: ASCO 2023 | PSMA PET ratio predicts response to [177Lu]PSMA radioligand therapy: a multicenter study
47. Smith CP, Proudfoot JA, Boutros PC, Reiter RE, Valle L, Rettig MB, Nickols NG, Feng FY, Nguyen PL, Nagar H, Spratt DE, Attard G, Weiner A, Weidhaas JB, Calais J, Ma TM, Davicioni E, Xiang M, Kishan AU. Transcriptomic Heterogeneity in High-risk Prostate Cancer and Implications for Extraprostatic Disease at Presentation on Prostate-specific Membrane Antigen Positron Emission Tomography. Eur Urol Oncol. 2023 Mar 2:S2588-9311(23)00041-X. doi: 10.1016/j.euo.2023.02.009. PMID: 36870853
48. Ma T, Czernin J, Felix C, Alano R, Wilhalme H, Valle L, Steinberg M, Dahlbom M, Reiter R, Rettig M, Cao M, Calais J, Kishan AU. LUNAR: a randomized Phase 2 study of 177 Lutetium-PSMA Neoadjuvant to Ablative Radiotherapy for Oligorecurrent Prostate Cancer (clinical trial protocol). BJU Int. 2023 Feb 16. doi: 10.1111/bju.15988. PMID: 36797449
49. Smith CP, Xiang M, Armstrong WR, Nickols NG, Steinberg ML, Reiter RE, Rettig M, Weiner AB, Shen J, Valle L, Czernin J, Calais J, Kishan AU. Patterns of Failure in Men With Radiorecurrent Prostate Cancer: A Post Hoc Analysis of 3 Prospective Gallium 68 Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Trials. Int J Radiat Oncol Biol Phys. 2023 Mar 1:S0360-3016(23)00181-5. PMID: 36863416
50. Sonni I, Dal Pra A, O'Connell DP, Ells Z, Benz M, Nguyen K, Yoon SM, Deng J, Smith C, Grogan T, Nickols NG, Cao M, Kishan AU, Calais J. PSMA PET/CT-based Atlas for Prostatic Bed Recurrence after Radical Prostatectomy: Clinical Implications for Salvage Radiation Therapy Contouring Guidelines. J Nucl Med. 2023 Feb 9:jnumed.122.265025. doi: 10.2967/jnumed.122.265025. PMID: 36759200 
    PSMA PET Improves Decision Making for Prostate Cancer Treatment
51. Gudenkauf LM, Chavez M, Maconi ML, Geiss C, Seyedroudbari A, Thin P, Hoogland AI, Nguyen K, Murthy V, Armstrong WR, Komrokji K, Oswald LB, Jim HSL, El-Haddad G, Fendler WP, Herrmann K, Cella D, Czernin J, Hofman MS, Dicker AP, Calais J, Tagawa ST, Gonzalez BD. Developing a novel patient reported outcomes measure for prostate cancer patients receiving radionuclide therapy. J Nucl Med. 2023;64(6):869-872. doi:10.2967/jnumed.122.264946
    Moffit: Moffitt Researchers Develop Tool to Measure Patient Health and Well-Being after Radionuclide Therapy
52. Meyer C, Prasad V, Stuparu A, Kletting P, Glatting G, Miksch J, Solbach C, Lueckerath K, Nyiranshuti L, Zhu S, Czernin J, Beer AJ, Slavik R, Calais J, Dahlbom M. Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225. EJNMMI Res. 2022 Oct 1;12(1):65. doi: 10.1186/s13550-022-00935-6. PMID: 36182983
53. Gafita A, Rauscher I, Fendler WP, Murthy V, Hui W, Armstrong WR, Herrmann K, Weber WA, Calais J, Eiber M, Weber M, Benz MR. Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria. Eur J Nucl Med Mol Imaging. 2022 Oct;49(12):4271-4281. doi: 10.1007/s00259-022-05882-x. PMID: 35767071
54. Gafita A, Rauscher I, Weber M, Hadaschik B, Wang H, Armstrong WR, Tauber R, Grogan TR, Czernin J, Rettig MB, Herrmann K, Calais J, Weber WA, Benz M, Fendler WP, Eiber M. Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study. J Nucl Med. 2022 Nov;63(11):1651-1658. PMID: 35422442 + SNMMI Alavi–Mandell Award 2023 +
55. Morath V, Heider M, Mittelhäuser M, Rolbieski H, Stroh J, Calais J, Eiber M, Bassermann F, Weber WA. Initial evaluation of [18F]-FACBC for PET imaging of multiple myeloma. EJNMMI Res. 2022 Jan 31;12(1):4. doi: 10.1186/s13550-022-00876-0. PMID: 35099620
56. Hotta M, Gafita A, Czernin J, Calais J.Outcome of patients with PSMA-PET/CT screen failure by VISION criteria and treated with 177Lu-PSMA therapy: a multicenter retrospective analysis. J Nucl Med. 2022 Oct;63(10):1484-1488. PMID: 35273096
    Cancer Network: Low/No PSMA Expressing mCRPC Tumors Respond Poorly to 177Lu-PSMA-617 Therapy
57. Xiang M, Ma TM, Savjani R, Pollom EL, Karnes RJ, Grogan T, Wong JK, Motterle G, Tosoian JJ, Trock BJ, Klein EA, Stish BJ, Dess RT, Spratt DE, Pilar A, Reddy C, Levin-Epstein R, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Huland H, Tran PT, Martin S, Martinez-Monge R, Krauss DJ, Abu-Isa EI, Alam R, Schwen Z, Pisansky TM, Choo CR, Song DY, Greco S, Deville C, McNutt T, DeWeese TL, Ross AE, Ciezki JP, Boutros PC, Nickols NG, Bhat P, Shabsovich D, Juarez JE, Chong N, Kupelian PA, Rettig MB, Zaorsky NG, Berlin A, Tward JD, Davis BJ, Reiter RE, Steinberg ML, Elashoff D, Horwitz EM, Tendulkar RD, Tilki D, Czernin J, Gafita A, Romero T, Calais J, Kishan AU. Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer. JAMA Netw Open. 2021 Dec 1;4(12):e2138550. PMID: 34902034
    Health Imaging: PSMA PET/CT and Prostate Cancer Outcomes
    EurekAlert!: UCLA-led study provides first indirect evidence that PSMA PET/CT surpasses conventional imaging in detecting occult prostate cancer spread and predicting long-term course and outcomes
    Medscape: PSMA PET/CT Validated as Imaging Modality in Prostate Cancer
58. Martin Ma T, Roy S, Wu X, Mantz C, Fuller D, Miszczyk L, Napieralska A, Namysł-Kaletka A, Bagshaw HP, Buyyounouski MK, Glicksman R, Andrew Loblaw D, Katz A, Upadhyaya SK, Nickols N, Steinberg ML, Philipson R, Aghdam N, Suy S, Pepin A, Collins SP, Boutros P, Rettig MB, Calais J, Wang M, Zaorsky N, Kishan AU.Refining the Definition of Biochemical Failure in the Era of Stereotactic Body Radiation Therapy for Prostate Cancer: the Phoenix Definition and Beyond. Radiother Oncol. 2021 Nov 10:S0167-8140(21)08797-1. doi: 10.1016/j.radonc.2021.11.005. PMID: 34774650
59. Mona CE, Benz MR, Hikmat F, Grogan TR, Lückerath K, Razmaria A, Riahi R, Slavik R, Girgis MD, Carlucci G, Kelly KA, French SW, Czernin J, Dawson DW, Calais J. Correlation of 68Ga-FAPi-46 PET biodistribution with FAP expression by immunohistochemistry in patients with solid cancers: a prospective translational exploratory study. J Nucl Med. 2021 Nov 5:jnumed.121.262426. doi: 10.2967/jnumed.121.262426. PMID: 34740953
    AuntMinnie: PET imaging lays foundation for new cancer therapies
60. Crompton J, Armstrong WR, Eckardt MA, Seyedroudbari A, Tap WD, Dry SM, Abt ER, Calais J, Herrmann K, Czernin J, Eilber FC, Benz MR. 18F-FLT PET/CT as a prognostic imaging biomarker of disease specific survival in patients with primary soft tissue sarcoma. J Nucl Med. 2022;63(5):708-712. doi:10.2967/jnumed.121.262502
61. Sonni I, Felker ER, Lenis AT, Sisk AE, Bahri S, Allen-Auerbach MS, Armstrong WR, Suvannarerg V, Tubtawee T, Grogan T, Elashoff D, Eiber M, Raman SS, Czernin J, Reiter R, Calais J. Head-to-head comparison of 68Ga-PSMA-11 PET/CT and mpMRI with histopathology gold-standard in the detection, intra-prostatic localization and local extension of primary prostate cancer: results from a prospective single-center imaging trial. J Nucl Med. 2022;63(6):847-854. doi:10.2967/jnumed.121.262398 
    + Featured article of the month + 
    Urology Times: PSMA and MRI for Early Prostate Cancer Detection
62. Ferdinandus J, Fendler WP, Farolfi A, Washington S, Mohammad O, Pampaloni MH, Scott PJ, Rodnick M, Viglianti BL, Eiber M, Herrmann K, Czernin J, Armstrong WR, Calais J, Hope TA, Piert MA. PSMA PET validates higher rates of metastatic disease for European Association of Urology Biochemical Recurrence Risk Groups: an international multicenter study. J Nucl Med. 2022;63(1):76-80. doi:10.2967/jnumed.121.262821
    + SNMMI Alavi–Mandell Award 2023 +
    Health Imaging: EUAs and Prostate Cancer Recurrence Risk
63. Abghari-Gerst M, Armstrong WR, Nguyen K, Calais J, Czernin J, Lin D, Jariwala N, Rodnick M, Hope TA, Hearn J, Montgomery JS, Alva A, Reichert ZR, Spratt DE, Johnson TD, Scott PJH, Piert M. A comprehensive assessment of 68Ga-PSMA-11 PET in biochemically recurrent prostate cancer: Results from a prospective multi-center study in 2005 patients. J Nucl Med. 2022;63(4):567-572. doi:10.2967/jnumed.121.262412
    Health Imaging: PSMA PET in UCLA Prostate Cancer Research
    DocWire News: 68Ga-PSMA-11 PET Specificity for Pelvic Nodal Metastases
64. Hope TA, Eiber M, Armstrong WR, Juarez R, Murthy V, Lawhn-Heath C, Behr SC, Zhang L, Barbato F, Ceci F, Farolfi A, Schwarzenböck SM, Unterrainer M, Zacho HD, Nguyen HG, Cooperberg MR, Carroll PR, Reiter RE, Holden S, Herrmann K, Zhu S, Fendler WP, Czernin J, Calais J. Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging Trial. JAMA Oncol. 2021;7(11):1635-1642. doi:10.1001/jamaoncol.2021.3771
    Health Imaging: ‘Practice changing’: New research underscores clinical benefits of PSMA-PET for prostate cancer
    GU Oncology Now: 68Ga-PSMA-11 PET Has Specificity of 0.95 for Pelvic Nodal Metastases